CRKL is an inclusion criterion in 24 clinical trials for malignant solid tumor, of which 19 are open and 5 are closed. Of the trials that contain CRKL status and malignant solid tumor as inclusion criteria, 14 are phase 1 (11 open), 3 are phase 1/phase 2 (3 open), and 7 are phase 2 (5 open) [4].

CRKL is an inclusion criterion in 8 clinical trials for non-small cell lung carcinoma, of which 7 are open and 1 is closed. Of the trials that contain CRKL status and non-small cell lung carcinoma as inclusion criteria, 5 are phase 1 (5 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (0 open) [4].

CRKL is an inclusion criterion in 6 clinical trials for breast carcinoma, of which 6 are open and 0 are closed. Of the trials that contain CRKL status and breast carcinoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), and 2 are phase 2 (2 open) [4].

CRKL is an inclusion criterion in 5 clinical trials for melanoma, of which 5 are open and 0 are closed. Of the trials that contain CRKL status and melanoma as inclusion criteria, 2 are phase 1 (2 open) and 3 are phase 1/phase 2 (3 open) [4].

CRKL is an inclusion criterion in 5 clinical trials for non-hodgkin lymphoma, of which 4 are open and 1 is closed. Of the trials that contain CRKL status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 4 are phase 2 (3 open) [4].

CRKL is an inclusion criterion in 3 clinical trials for colorectal carcinoma, of which 3 are open and 0 are closed. Of the trials that contain CRKL status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (2 open) [4].

CRKL is an inclusion criterion in 3 clinical trials for histiocytic and dendritic cell neoplasm, of which 2 are open and 1 is closed. Of the trials that contain CRKL status and histiocytic and dendritic cell neoplasm as inclusion criteria, 3 are phase 2 (2 open) [4].

CRKL is an inclusion criterion in 2 clinical trials for glioma, of which 2 are open and 0 are closed. Of the trials that contain CRKL status and glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

CRKL is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain CRKL status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [4].

CRKL is an inclusion criterion in 2 clinical trials for hepatocellular carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CRKL status and hepatocellular carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

CRKL is an inclusion criterion in 2 clinical trials for low grade glioma, of which 2 are open and 0 are closed. Of the trials that contain CRKL status and low grade glioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

CRKL is an inclusion criterion in 2 clinical trials for myelodysplastic syndromes, of which 2 are open and 0 are closed. Of the trials that contain CRKL status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

CRKL is an inclusion criterion in 2 clinical trials for ovarian carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CRKL status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

CRKL is an inclusion criterion in 2 clinical trials for renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CRKL status and renal cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [4].

CRKL is an inclusion criterion in 2 clinical trials for squamous cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CRKL status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

CRKL is an inclusion criterion in 2 clinical trials for thyroid gland carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CRKL status and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

CRKL is an inclusion criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

CRKL is an inclusion criterion in 1 clinical trial for aggressive systemic mastocytosis, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and aggressive systemic mastocytosis as inclusion criteria, 1 is phase 1 (1 open) [4].

CRKL is an inclusion criterion in 1 clinical trial for astrocytic tumor, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and astrocytic tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CRKL is an inclusion criterion in 1 clinical trial for cancer, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and cancer as inclusion criteria, 1 is phase 1 (1 open) [4].

CRKL is an inclusion criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and chondrosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CRKL is an inclusion criterion in 1 clinical trial for chronic myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

CRKL is an inclusion criterion in 1 clinical trial for classical hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and classical hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CRKL is an inclusion criterion in 1 clinical trial for cutaneous melanoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and cutaneous melanoma as inclusion criteria, 1 is phase 1 (1 open) [4].

CRKL is an inclusion criterion in 1 clinical trial for desmoid-type fibromatosis, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and desmoid-type fibromatosis as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CRKL is an inclusion criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CRKL is an inclusion criterion in 1 clinical trial for dysembryoplastic neuroepithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and dysembryoplastic neuroepithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CRKL is an inclusion criterion in 1 clinical trial for embryonal rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and embryonal rhabdomyosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CRKL is an inclusion criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CRKL is an inclusion criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and Ewing sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CRKL is an inclusion criterion in 1 clinical trial for gangliocytoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and gangliocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CRKL is an inclusion criterion in 1 clinical trial for ganglioglioma, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and ganglioglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CRKL is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains CRKL status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

CRKL is an inclusion criterion in 1 clinical trial for hematologic and lymphocytic disorder, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and hematologic and lymphocytic disorder as inclusion criteria, 1 is phase 1 (1 open) [4].

CRKL is an inclusion criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 1 (1 open) [4].

CRKL is an inclusion criterion in 1 clinical trial for hematopoietic and lymphoid system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and hematopoietic and lymphoid system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].

CRKL is an inclusion criterion in 1 clinical trial for liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and liposarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CRKL is an inclusion criterion in 1 clinical trial for low-grade neuroepithelial tumor, NOS, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and low-grade neuroepithelial tumor, NOS as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CRKL is an inclusion criterion in 1 clinical trial for malignant peripheral nerve sheath tumor, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and malignant peripheral nerve sheath tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CRKL is an inclusion criterion in 1 clinical trial for mast cell leukemia, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and mast cell leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

CRKL is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) [4].

CRKL is an inclusion criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and myeloid neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].

CRKL is an inclusion criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and neuroblastoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CRKL is an inclusion criterion in 1 clinical trial for neurofibromatosis type 1, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and neurofibromatosis type 1 as inclusion criteria, 1 is phase 2 (1 open) [4].

CRKL is an inclusion criterion in 1 clinical trial for neuronal and mixed neuronal-glial tumors, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and neuronal and mixed neuronal-glial tumors as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CRKL is an inclusion criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and osteosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CRKL is an inclusion criterion in 1 clinical trial for pecoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and pecoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CRKL is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and pancreatic carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CRKL is an inclusion criterion in 1 clinical trial for peritoneal mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [4].

CRKL is an inclusion criterion in 1 clinical trial for pilocytic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and pilocytic astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CRKL is an inclusion criterion in 1 clinical trial for pilomyxoid astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and pilomyxoid astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CRKL is an inclusion criterion in 1 clinical trial for poorly differentiated thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and poorly differentiated thyroid gland carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CRKL is an inclusion criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and prostate carcinoma as inclusion criteria, 1 is phase 3 (1 open) [4].

CRKL is an inclusion criterion in 1 clinical trial for rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and rhabdoid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CRKL is an inclusion criterion in 1 clinical trial for schwannoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and schwannoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CRKL is an inclusion criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CRKL is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CRKL is an inclusion criterion in 1 clinical trial for systemic mastocytosis with an associated hematological neoplasm (SM-AHN), of which 1 is open and 0 are closed. Of the trial that contains CRKL status and systemic mastocytosis with an associated hematological neoplasm (SM-AHN) as inclusion criteria, 1 is phase 1 (1 open) [4].

CRKL is an inclusion criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CRKL is an inclusion criterion in 1 clinical trial for undifferentiated pleomorphic sarcoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and undifferentiated pleomorphic sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CRKL is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].